Topics

Glioblastoma | Treatment | Clinical trials

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials

□ OVERVIEW

□ UMBRELLA TRIALS

CHEMOTHERAPY

□ CARBOPLATIN

□ DRUG DELIVERY

□ IRINOTECAN

□ LOMUSTINE

□ LURBINECTEDIN

□ METHOXYAMINE

□ NEOADJUVANT CHEMOTHER

□ R-(-)-GOSSYPOL

□ TAXANES

□ TEMOZOLOMIDE

DIAGNOSIS / ASSESSMENT

□ OLFACTORY FUNCTION

□ POSITRON EMISS TOMOGR

ELECTRIC / MAGNETIC FIELDS

□ TUMOR TREATING FIELDS

GENE THERAPY

□ AGLATIMAGENE BESADENOVEC

IMMUNOTHERAPY

□ BISPECIF ANTIB ARMED T CELLS

□ CAR-T-CELLS

□ CELL THERAPY

□ DENDRITIC CELLS

□ GM-CSF

□ IMMUNE CHECKPOINT INHIBIT

□ VACCINES

□ VIRUSES

INTEGRATIVE MEDICINE

□ CIRCADIAN CLOCK

□ KETOGENIC METABOLIC THER

□ VITAMINS

LASER THERAPIES

□ LASER INTERSTITIAL THERMAL THER

NUCLEAR MEDICINE

□ THERANOSTICS

PHARMACOTHERAPY

□ ANTIEMETIC DRUGS

□ ANTIEPILEPTIC DRUGS

□ ANTISECRETORY FACTOR

□ ARSENICALS

□ CHLOROTOXIN

□ DISULFIRAM

□ IMMUNOSUPPRESSIVE DRUGS

RADIOTHERAPY

□ BORON NEUTRON CAPTURE THER

□ EXTERNAL BEAM RADIATION THER

□ FRACTIONATED

□ MARGINS

□ PHOTODYNAMIC THERAPY

□ PROTON BEAM

□ RADIOPHARMACEUTICALS

□ RADIOSENSITIZERS

□ RE-IRRADIATION

□ RESPONSE-ADAPTIVE

SIDE EFFECTS

□ THROMBOEMBOLISM

SUPPORTIVE CARE

□ PALLIATIVE CARE

SURGERY

□ BIOPSY

□ FLAIRECTOMY

□ FLUORESCENCE-GUIDED SURGERY

□ RESECTION CAVITY

□ RESECTION EXTENT

TARGETED THERAPY

□ ADAVOSERTIB

□ AFATINIB

□ ALECTINIB

□ APTAMERS

□ ATEZOLIZUMAB

□ BEVACIZUMAB

□ DASATINIB

□ DRUG SCREENING

□ GLUTAMATE SIGN INHIBITORS

□ IDASANUTLIN

□ IDO1 INHIBITORS

□ IPILIMUMAB

□ KHK2455

□ KINASE INHIBITORS

□ LENVATINIB

□ LISAVANBULIN

□ MARIZOMIB

□ MICROENV MODULATORS

□ MOGAMULIZUMAB

□ NAVTEMADLIN

□ NIVOLUMAB

□ OLAPARIB

□ PALBOCICLIB

□ PAMIPARIB

□ PD-L1 TARGETED THERAPY

□ PEMBROLIZUMAB

□ PEXIDARTINIB

□ RINDOPEPIMUT

□ RO7428731

□ SACITUZUMAB GOVITECAN

□ SUNITINIB

□ TEMSIROLIMUS

□ TISLELIZUMAB

□ VELIPARIB

□ VISMODEGIB

ULTRASOUND THERAPY

□ FOCUSED ULTRASOUND

VARIANTS

□ MOLECULAR GLIOBLASTOMA